These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 37127001)

  • 1. Efficacy and safety of sodium glucose cotransporter 2 inhibitors plus standard care in diabetic kidney disease: A systematic review and meta-analysis.
    Woodhams LM; Chalmers L; Sim TF; Yeap BB; Schlaich MP; Schultz C; Hillis GS
    J Diabetes Complications; 2023 Jun; 37(6):108456. PubMed ID: 37127001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
    Yang S; Zhao L; Mi Y; He W
    Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of combination therapy with sodium-glucose cotransporter 2 inhibitors and renin-angiotensin system blockers in patients with type 2 diabetes: a systematic review and meta-analysis.
    Tian B; Deng Y; Cai Y; Han M; Xu G
    Nephrol Dial Transplant; 2022 Mar; 37(4):720-729. PubMed ID: 33605424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of SGLT2 inhibitors combined with ACEI/ARBs in the treatment of type 2 diabetes mellitus: A meta-analysis of randomized controlled studies.
    Cai Y; Shi W; Xu G
    Expert Opin Drug Saf; 2020 Nov; 19(11):1497-1504. PubMed ID: 32881584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Bae JH; Park EG; Kim S; Kim SG; Hahn S; Kim NH
    Sci Rep; 2019 Sep; 9(1):13009. PubMed ID: 31506585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative safety of sodium-glucose co-transporter 2 inhibitors in elderly patients with type 2 diabetes mellitus and diabetic kidney disease: a systematic review and meta-analysis.
    Liu Y; An C; Liu P; Yang F; Zhao Q
    Ren Fail; 2023 Dec; 45(1):2217287. PubMed ID: 37246403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years.
    Liu XY; Zhang N; Chen R; Zhao JG; Yu P
    J Diabetes Complications; 2015; 29(8):1295-303. PubMed ID: 26365905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Diagnosis and Treatment of Diabetic Kidney Disease.
    Rodriguez F; Lee DJ; Gad SS; Santos MP; Beetel RJ; Vasey J; Bailey RA; Patel A; Blais J; Weir MR; Dash R
    Adv Ther; 2021 Aug; 38(8):4425-4441. PubMed ID: 34254257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits of SGLT2 inhibitors combining with renin-angiotensin-system blockers on cardiovascular outcomes in chronic kidney disease patients: A systemic review and meta-analysis.
    Liu T; Li R; Wang X; Gao X; Zhang X
    Med Clin (Barc); 2022 Jul; 159(2):65-72. PubMed ID: 34872768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A kidney diagnostic's impact on physician decision-making in diabetic kidney disease.
    Datar M; Ramakrishnan S; Chong J; Montgomery E; Goss TF; Coca SG; Vassalotti JA
    Am J Manag Care; 2022 Dec; 28(12):654-661. PubMed ID: 36525658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.
    Feng Y; Huang R; Kavanagh J; Li L; Zeng X; Li Y; Fu P
    Am J Cardiovasc Drugs; 2019 Jun; 19(3):259-286. PubMed ID: 30737754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: A systematic review and meta-analysis.
    Wang C; Zhou Y; Kong Z; Wang X; Lv W; Geng Z; Wang Y
    Diabetes Obes Metab; 2019 Apr; 21(4):1018-1026. PubMed ID: 30565382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early reduction in albuminuria is associated with a steeper 'dip' in initial estimated glomerular filtration rate but favourable long-term kidney outcomes in people with diabetes receiving sodium-glucose cotransporter-2 inhibitors.
    Kao YW; Yen KC; Chen SW; Chao TF; Chan YH
    Diabetes Obes Metab; 2024 Sep; 26(9):3868-3879. PubMed ID: 38951860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy of individual renin-angiotensin system inhibitors on major renal outcomes in diabetic kidney disease: a network meta-analysis.
    Cai J; Huang X; Zheng Z; Lin Q; Peng M; Shen D
    Nephrol Dial Transplant; 2018 Nov; 33(11):1968-1976. PubMed ID: 29579289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of traditional Chinese medicine and angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and sodium glucose cotransporter inhibitors in patients with diabetic kidney disease: A systematic review and network meta-analysis.
    Zhang L; Miao R; Yu T; Wei R; Tian F; Huang Y; Tong X; Zhao L
    Pharmacol Res; 2022 Mar; 177():106111. PubMed ID: 35183713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.
    Alicic RZ; Johnson EJ; Tuttle KR
    Am J Kidney Dis; 2018 Aug; 72(2):267-277. PubMed ID: 29866460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials.
    Fletcher RA; Jongs N; Chertow GM; McMurray JJV; Arnott C; Jardine MJ; Mahaffey KW; Perkovic V; Rockenschaub P; Rossing P; Correa-Rotter R; Toto RD; Vaduganathan M; Wheeler DC; Heerspink HJL; Neuen BL
    J Am Soc Nephrol; 2023 Dec; 34(12):1965-1975. PubMed ID: 37876229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of ACE Inhibitors and Angiotensin Receptor Blockers in Normotensive Patients with Diabetic Kidney Disease.
    He D; Zhang Y; Zhang W; Xing Y; Guo Y; Wang F; Jia J; Yan T; Liu Y; Lin S
    Horm Metab Res; 2020 May; 52(5):289-297. PubMed ID: 32219798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
    Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V
    Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis.
    Kaze AD; Zhuo M; Kim SC; Patorno E; Paik JM
    Cardiovasc Diabetol; 2022 Mar; 21(1):47. PubMed ID: 35321742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.